source
- Novo Holdings invests €500 million in Europe-focused fund as Alnylam advances second obesity drug to clinicNovo Holdings, the investment arm of the Novo Nordisk Foundation, has committed €500 million to the Scaleup Europe Fund, a vehicle aimed at supporting European biotech scale‑ups. Alnylam Pharmaceu…
- Alnylam partners with Inceptive Nucleics on AI deal that could reach $2 billionAlnylam Pharmaceuticals announced a partnership with Inceptive Nucleics to apply artificial‑intelligence tools to its RNA‑based drug discovery program. The agreement provides an upfront $30 millio…